Development of a neutralization assay for Nipah virus using pseudotype particles

Area of Science:

• Virology
• Immunology
• Diagnostic Assay Development

Background:

• Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic zoonotic paramyxoviruses requiring Biosafety Level 4 (BSL-4) containment.
• The plaque reduction neutralization test (PRNT) is a standard method for detecting antibodies to NiV and HeV, but it is labor-intensive, time-consuming, and requires BSL-4 facilities.

Purpose of the Study:

• To develop and validate a rapid, safe, and cost-effective neutralization assay for NiV and HeV.
• To establish an alternative to the traditional PRNT that can be performed in lower biosafety containment levels.

Main Methods:

• Development of a pseudotyped vesicular stomatitis virus (VSV) system expressing NiV and HeV fusion (F) and attachment (G) glycoproteins (pVSV-NiV-F/G).
• Evaluation of the pVSV-NiV-F/G neutralization assay using serum samples from NiV outbreak investigations and a swine vaccination study.
• Comparison of results from the novel pseudotype assay with those obtained from the standard PRNT.

Main Results:

• The pseudotyped VSV neutralization assay (pVSV-NiV-F/G) demonstrated good correlation with the standard PRNT results.
• The assay can be performed at Biosafety Level 2 (BSL-2), significantly reducing containment requirements.
• The method proved effective in analyzing over 300 serum samples from a swine vaccination study.

Conclusions:

• The developed VSV pseudotype neutralization assay is a rapid, cost-effective, and reliable alternative to the PRNT for detecting NiV and HeV antibodies.
• This assay has significant potential for diagnostic applications, especially in resource-limited settings lacking high-containment facilities.
• It offers a valuable tool for epidemiological surveillance, basic research, and vaccine development against NiV and HeV.